Access to medicines
Europe's pharmaceutical sector is stepping up measures to help deliver faster, more equitable access to medicines for millions of patients across the EU.
Inequitable and delayed access to medicines continues to challenge Europe’s healthcare systems and negatively impact the health outcomes of its citizens. But the pharmaceutical industry believes we can achieve more equitable and faster access across Europe if stakeholders come together to tackle the issues delaying delivery of innovative medicines. EFPIA is laying out a number of concrete proposals so as an industry we can play our part in addressing the key barriers to access.
EFPIA’s plans include committing to file pricing and reimbursement (P&R) applications in all EU countries as quickly as possible and no later than two years after receiving the EU Marketing Authorisation as well as creating a portal that will provide timely information and important insights as medicines move through Europe’s P&R processes. Building a shared understanding of the delays and barriers to access will allow all stakeholders to address the issues in partnership.
As more complex and potentially curative medicines flow through companies’ pipelines, the need to act is greater than ever. We are already seeing the benefits modern medicines can deliver to patients, their families, and society as they radically alter disease progression and improve survival rates across multiple disease areas. More advances in prevention and patient care look set to be realised thanks to the more than 8,000 medicines currently in development.
>> Learn more about EFPIA's concrete proposals to improve patient access to innovative medicines <<